Theralase Technologies Stock Performance
| TLTFF Stock | USD 0.19 0.01 5.00% |
Theralase Technologies has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 0.58, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Theralase Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Theralase Technologies is expected to be smaller as well. Theralase Technologies right now has a risk of 5.57%. Please validate Theralase Technologies jensen alpha, semi variance, price action indicator, as well as the relationship between the maximum drawdown and daily balance of power , to decide if Theralase Technologies will be following its existing price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Theralase Technologies are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly unfluctuating technical and fundamental indicators, Theralase Technologies may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
| Begin Period Cash Flow | 7.9 M | |
| Total Cashflows From Investing Activities | -100.8 K |
Theralase |
Theralase Technologies Relative Risk vs. Return Landscape
If you would invest 19.00 in Theralase Technologies on November 4, 2024 and sell it today you would earn a total of 0.00 from holding Theralase Technologies or generate 0.0% return on investment over 90 days. Theralase Technologies is currently producing 0.1549% returns and takes up 5.5688% volatility of returns over 90 trading days. Put another way, 49% of traded otc stocks are less volatile than Theralase, and 97% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Theralase Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theralase Technologies' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Theralase Technologies, and traders can use it to determine the average amount a Theralase Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0278
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TLTFF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.57 actual daily | 49 51% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Theralase Technologies is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theralase Technologies by adding it to a well-diversified portfolio.
Theralase Technologies Fundamentals Growth
Theralase OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Theralase Technologies, and Theralase Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Theralase OTC Stock performance.
| Return On Equity | -1.13 | |||
| Return On Asset | -0.59 | |||
| Operating Margin | (5.50) % | |||
| Current Valuation | 51.77 M | |||
| Shares Outstanding | 216.5 M | |||
| Price To Earning | (9.16) X | |||
| Price To Book | 20.01 X | |||
| Price To Sales | 52.92 X | |||
| Revenue | 780.64 K | |||
| EBITDA | (4.13 M) | |||
| Cash And Equivalents | 1.46 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 494.32 K | |||
| Debt To Equity | 0.19 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (4.03 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 5.94 M | |||
About Theralase Technologies Performance
By analyzing Theralase Technologies' fundamental ratios, stakeholders can gain valuable insights into Theralase Technologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Theralase Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Theralase Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada. Theralase Technologi operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about Theralase Technologies performance evaluation
Checking the ongoing alerts about Theralase Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Theralase Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Theralase Technologies had very high historical volatility over the last 90 days | |
| Theralase Technologies has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 780.64 K. Net Loss for the year was (4.41 M) with profit before overhead, payroll, taxes, and interest of 278.88 K. | |
| Theralase Technologies has accumulated about 1.46 M in cash with (4.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. |
- Analyzing Theralase Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Theralase Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Theralase Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Theralase Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Theralase Technologies' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Theralase Technologies' otc stock. These opinions can provide insight into Theralase Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Theralase OTC Stock analysis
When running Theralase Technologies' price analysis, check to measure Theralase Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theralase Technologies is operating at the current time. Most of Theralase Technologies' value examination focuses on studying past and present price action to predict the probability of Theralase Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theralase Technologies' price. Additionally, you may evaluate how the addition of Theralase Technologies to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |